STOCK TITAN

LEMAITRE VASCULAR (LMAT) SEC Filings, Aug-Sep 2025

LMAT NASDAQ

LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.

Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.

Rhea-AI Summary

LeMaitre Vascular director John James O'Connor reported changes in beneficial ownership on Form 4 relating to dividend equivalent rights that accrued on previously granted equity awards. The filing shows transactions dated 09/04/2025 recording a series of small accruals of dividend equivalent rights tied to restricted stock units and performance share unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock. The filing was signed by Nathan Ulrich on 09/08/2025. The report indicates the form was filed by one reporting person who is a director of the issuer (LMAT).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
-
Rhea-AI Summary

Lawrence J. Jasinski, a director of LeMaitre Vascular, Inc. (LMAT), reported on Form 4 that on 09/04/2025 he received dividend equivalent rights tied to previously granted equity awards. The Form 4 lists five separate accruals of dividend equivalent rights that arose from restricted stock unit and performance stock unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of common stock and vests proportionately with the underlying award. The filing shows fractional share amounts for each accrual and the number of shares beneficially owned following the transactions. The Form 4 was signed by Nathan Ulrich on 09/08/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
-
Rhea-AI Summary

LeMaitre Vascular insider report: This Form 4, filed for Trent G. Kamke (Senior V.P., Operations), discloses accrual and acquisition of dividend equivalent rights tied to restricted stock unit (RSU) and performance share unit (PSU) awards that vest proportionately. Transactions are dated 09/04/2025. The report lists multiple accruals that convert economically to common shares, with individual tranche amounts shown (examples: 0.3386, 0.6173, 1.2562, 1.6108, 1.9307, 1.9194). No cash consideration is reported and ownership form is direct. The filing documents routine compensation-related accruals rather than open-market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
Rhea-AI Summary

LeMaitre Vascular Inc. (LMAT) Form 4: Dorian Paul LeBlanc, identified as Chief Financial Officer and a director, reported a transaction dated 09/04/2025. The filing records the acquisition of dividend equivalent rights that accrued on a restricted stock unit award originally granted on 03/10/2025. Each dividend equivalent right is the economic equivalent of one share of the company’s common stock. The report shows an acquisition at $0 and a post-transaction beneficial ownership figure of 8.4578 (direct). The form is signed on the filing by Nathan Ulrich on 09/08/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
-
Rhea-AI Summary

LeMaitre Vascular, Inc. (LMAT) reporting person Joseph P. Pellegrino Jr., a company director, reported accruals of dividend equivalent rights on 09/04/2025 tied to previously granted restricted stock unit (RSU) and performance share unit (PSU) awards. The filing itemizes seven separate dividend-equivalent accruals that vest proportionately with their underlying awards, referencing grant dates from 12/2/2020 through 12/6/2024. The report shows the reporting person acquired 19.0048 dividend equivalent rights on 09/04/2025, which correspond to 176.2176 shares of common stock economic equivalent following the transactions. The entries are non-cash accruals (price listed as $0) and were certified by signature on 09/08/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
-
Rhea-AI Summary

David B. Roberts, serving as President and Director of LeMaitre Vascular, acquired a series of dividend equivalent rights tied to previously granted restricted stock units and performance share units. The rights, recorded on 09/04/2025, represent the economic equivalent of shares of the issuer's common stock and arise from awards dated 12/2/2020, 12/11/2021, 12/12/2022, 12/8/2023, 12/6/2024 and 2/18/2025. The reported increments of dividend equivalent rights total 18.5799 share-equivalents across eight award lines, each showing zero purchase price and classified as direct ownership. The table lists the post-transaction beneficially owned share-equivalents for each line, indicating modest accruals that vest proportionately with the underlying awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
insider
Rhea-AI Summary

LeMaitre Vascular, Inc. (LMAT) insider report: George W. LeMaitre, Chairman and CEO, reported transactions on 09/03/2025 showing two non-derivative dispositions of 10,600 shares each (transaction code G), reducing his reported beneficial ownership from 1,716,403 to 1,705,803 shares following the second line item. The filing also records multiple dividend equivalent rights credited on restricted stock and performance share unit awards that convert economically to common shares; individual accruals range from 2.0944 to 10.238 and represent fractional share equivalents under vesting schedules. The form is signed and dated 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
insider
-
Rhea-AI Summary

LeMaitre Vascular insider sale disclosed on Form 4. Director Lawrence J. Jasinski sold 976 shares of Common Stock on 08/12/2025 at $92.78 per share, and after the transaction beneficially owned 4,773 shares directly. The filing lists the issuer as LeMaitre Vascular, Inc. (LMAT) and indicates the Form 4 was filed as an individual report. The document contains no options or other derivative transactions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.10%
Tags
insider
-
Rhea-AI Summary

LeMaitre Vascular President and Director David B. Roberts reported option exercises and subsequent open-market sales on 08/11/2025. The Form 4 shows Mr. Roberts acquiring shares upon exercise of previously granted stock options and selling multiple blocks of common stock the same day.

The filing lists option exercises generating 3,979, 123 and 6,713 shares at exercise prices of $37.29 and $35.48. On 08/11/2025 he sold blocks of 3,718, 384 and 6,713 shares at weighted average prices of $92.5337, $91.5484 and $92.3549, respectively. The filing shows beneficial ownership of 17,976 shares following these transactions. The Form is signed by Nathan Ulrich on 08/13/2025 as submitted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
insider
Rhea-AI Summary

Bridget A. Ross, a director of LeMaitre Vascular (LMAT), reported exercising 2,500 vested stock options on 08/08/2025 with an exercise price of $37.29, and concurrently selling 2,500 common shares at $94.00 per share. The option exercised was fully vested and had an expiration date of 12/02/2025. The sequence increased her direct holdings to 5,416 shares then, after the sale, left her with 2,916 shares of common stock beneficially owned.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
insider

FAQ

How many LEMAITRE VASCULAR (LMAT) SEC filings are available on StockTitan?

StockTitan tracks 120 SEC filings for LEMAITRE VASCULAR (LMAT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for LEMAITRE VASCULAR (LMAT)?

The most recent SEC filing for LEMAITRE VASCULAR (LMAT) was filed on November 5, 2026.